Natera (NASDAQ:NTRA) Insider Sells $378,232.03 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,639 shares of Natera stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $230.77, for a total value of $378,232.03. Following the transaction, the insider directly owned 137,847 shares in the company, valued at $31,810,952.19. The trade was a 1.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, February 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $231.44, for a total value of $694,320.00.
• On Wednesday, January 28th, Solomon Moshkevich sold 1,200 shares of Natera stock. The shares were sold at an average price of $237.66, for a total transaction of $285,192.00.
• On Tuesday, January 27th, Solomon Moshkevich sold 1,013 shares of Natera stock. The stock was sold at an average price of $240.53, for a total value of $243,656.89.
• On Wednesday, January 21st, Solomon Moshkevich sold 293 shares of Natera stock. The shares were sold at an average price of $235.00, for a total value of $68,855.00.
• On Tuesday, January 20th, Solomon Moshkevich sold 23,205 shares of Natera stock. The shares were sold at an average price of $234.74, for a total value of $5,447,141.70.
• On Friday, January 2nd, Solomon Moshkevich sold 2,951 shares of Natera stock. The shares were sold at an average price of $228.95, for a total transaction of $675,631.45.
• On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The stock was sold at an average price of $230.76, for a total transaction of $1,082,725.92.
• On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $238.15, for a total transaction of $714,450.00.

Natera Trading Down 9.7%

Shares of NTRA stock traded down $22.07 during trading on Wednesday, hitting $205.61. The company’s stock had a trading volume of 2,452,176 shares, compared to its average volume of 1,059,726. The company has a market cap of $28.44 billion, a PE ratio of -89.79 and a beta of 1.64. The business has a fifty day moving average of $234.95 and a 200-day moving average of $195.74. Natera, Inc. has a 52 week low of $125.38 and a 52 week high of $256.36.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The business had revenue of $592.18 million during the quarter, compared to analysts’ expectations of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The firm’s revenue for the quarter was up 34.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.26) EPS. As a group, research analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Institutional Trading of Natera

A number of hedge funds and other institutional investors have recently bought and sold shares of NTRA. Vanguard Group Inc. boosted its holdings in Natera by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company’s stock valued at $2,141,594,000 after purchasing an additional 282,826 shares during the period. JPMorgan Chase & Co. raised its position in shares of Natera by 9.4% in the third quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock worth $1,871,914,000 after buying an additional 1,003,129 shares in the last quarter. State Street Corp boosted its stake in Natera by 2.2% during the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after buying an additional 72,087 shares during the period. Franklin Resources Inc. grew its position in Natera by 37.5% during the third quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock worth $428,987,000 after buying an additional 727,366 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Natera by 7.0% in the 2nd quarter. Geode Capital Management LLC now owns 2,552,725 shares of the medical research company’s stock worth $430,640,000 after acquiring an additional 166,768 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Analyst Ratings Changes

NTRA has been the subject of several research analyst reports. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Citigroup began coverage on Natera in a report on Wednesday, January 7th. They set a “buy” rating and a $300.00 price objective for the company. Wells Fargo & Company boosted their target price on Natera from $190.00 to $205.00 and gave the company an “equal weight” rating in a research note on Monday, December 15th. Guggenheim increased their price target on Natera from $230.00 to $270.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Finally, BNP Paribas Exane upgraded Natera to a “hold” rating and set a $172.00 price objective on the stock in a research note on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $249.20.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.